DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...
Exploring Molecular Switches Application In Modern Therapeutics Download Report
Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell ...
Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...